Malika Ammam, PhD,  —

Malika Ammam received her MS degree from the University of Pierre et Marie CURIE in July 2002 and her PhD from the University of Paris Sud XI, France in September 2005. From 2006 to 2007, she worked as a research fellow at the University of Kansas in collaboration with Pinnacle Technology Inc. (USA). From 2007 to 2010, she was a research associate at KU Leuven, Belgium. From 2010 to 2012, she worked at the University of Ontario Institute of Technology in collaboration with Alcohol Countermeasure Systems Corporation, Canada. She held a prestigious Rosalind Franklin fellowship and resigned in 2015. Now, she is a freelancer.

Articles by Malika Ammam

Potential PAH Therapy, Trevyent, Being Readied to Request FDA Approval

SteadyMed announced that it recently completed the manufacturing of required batches of its drug candidate Trevyent, designed to treat pulmonary arterial hypertension (PAH). The work will allow the company to evaluate the therapy’s shelf-life in advance of submitting a New Drug Application to the U.S. Food and Drug Administration (FDA) early next year.

Karos Advancing Its Small Molecule Drug Candidate to Treat PAH, KAR5585, in Clinical Testing

Karos Pharmaceuticals announced that is advancing its small molecule drug candidate, KAR5585, in clinical testing as a treatment for pulmonary arterial hypertension (PAH) and other rare diseases characterized by fibrosis. A number of agents have recently been introduced as therapeutic drugs for PAH. Among them, KAR5585 is a first-in-class, selective inhibitor of an enzyme…

PH Study Finds Genetic ‘Junk’ May Play Key Role in Disease

A recent study suggests that RNA fragments called microRNAs (miRNAs), long thought of as genetic “junk,” actually control the production of endothelial cells, whose over-proliferation is responsible for the development of pulmonary hypertension (PH). The study, published in the Experimental Biology and Medicine journal, is titled “microRNA-125a in pulmonary…

Therapy Options Exist for PAH Patients Unresponsive to Medications

A recent perspective study explores catheter therapies as an alternative treatment for patients with pulmonary arterial hypertension (PAH) who do not respond well to traditional medication. The paper, written by a researcher from the Division of Cardiovascular Medicine at Brigham and Women’s Hospital in Boston, is titled “Catheter-Based Therapies for Patients With…

Pulmonary Arterial Hypertension Frequent in African HIV Patients

A recent review study has found that patients with HIV in Africa have a higher than average prevalence of developing pulmonary arterial hypertension (PAH). The study, entitled “HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment,” was published in the AIDS Research and…

Study Tracks Pulmonary Hypertension Patients Through Orthopedic Surgery

Recently published research reveals that orthopedic (musculoskeletal) surgery in patients with pulmonary hypertension (PH), while challenging, is feasible and offers decent outcomes even in severe stages of the disease, provided proper care is given. The paper entitled “Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations“ was published in…


A Conversation With Rare Disease Advocates